We are proud to announce that APICES has been acknowledged for its ongoing collaboration in the CABOMAYOR Trial, a Phase II clinical trial in metastatic renal cell carcinoma (mRCC). This acknowledgement was highlighted in the Journal of Geriatric Oncology.
APICES has contributed extensively to critical aspects throughout the trial, including start-up, coordination, project management, monotoring, pharmacovigilance, data management, biostatistics, and medical writing activities.
This acknowledgment is a great motivation for the entire APICES team to continue the commitment we bring to every project we collaborate on. We sincerely thank Spanish Oncology Genitourinary Group (SOGUG) and Dr. Miguel Ángel Climent for giving us the opportunity to support the study as CRO and for including us acknowledgments. We also congratulate them and all investigators and patients on the CABOMAYOR trial progress and results.
The CABOMAYOR Trial was aimed at evaluating the efficacy tolerability of anticancer drugs in terms of objective response rate in previously untreated fragile older patients with metastatic renal cell carcinoma (mRCC).
For further information about the CABOMAYOR Trial, please visit: Pilot phase 2 study of the efficacy, safety, and tolerability of first-line cabozantinib for older fragile patients with metastatic renal cell carcinoma: The SOGUG-CABOMAYOR study – ScienceDirect
Get the latest clinical insights delivered to your feed or inbox!
Key Takeaways: First-in-human trials in the EU are governed by Regulation (EU) No 536/2014 and the EMA’s first-in-human guideline (EMEA/CHMP/SWP/28367/07 Rev 1). Sponsors must submit a complete Clinical Trial Application via the CTIS portal and obtain both Part I...
Key Takeaways: Phase I dose escalation design in the EU is governed by ICH E8(R1), EMA first-in-human guidance (EMA/CHMP/SWP/28367/07 Rev.1), and EU Clinical Trial Regulation 536/2014 via CTIS. The classical 3+3 design is increasingly replaced by model-based...
EU MDR clinical investigation requirements have fundamentally changed how Medtech sponsors plan and execute device studies in Europe. Regulation (EU) 2017/745 replaced the clinical investigation provisions of Directive 93/42/EEC (MDD) and introduced a more stringent, harmonised framework across all 27 EU member states. For sponsors running investigations in Spain, Germany, France, the Netherlands, or any other member state, understanding which pathway applies to their study is the single most consequential regulatory decision before CIP submission.
